{"id":"abraxane-maintenance","safety":{"commonSideEffects":[{"rate":"≈20–30%","effect":"Peripheral neuropathy"},{"rate":"≈15–25%","effect":"Neutropenia"},{"rate":"≈10–20%","effect":"Anemia"},{"rate":"≈15–25%","effect":"Fatigue"},{"rate":"≈10–20%","effect":"Alopecia"},{"rate":"≈10–15%","effect":"Nausea/vomiting"},{"rate":"≈10–15%","effect":"Arthralgia/myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Paclitaxel binds to beta-tubulin and prevents microtubule depolymerization, disrupting the mitotic spindle and halting cell cycle progression. The albumin-bound nanoparticle formulation improves drug delivery and reduces hypersensitivity reactions compared to conventional paclitaxel, allowing higher doses and potentially enhanced tumor penetration via the albumin receptor (gp60) on endothelial cells.","oneSentence":"Abraxane is a nanoparticle albumin-bound paclitaxel that stabilizes microtubules to inhibit cell division and induce apoptosis in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:44:00.001Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer (maintenance therapy)"},{"name":"Metastatic breast cancer"},{"name":"Pancreatic cancer"}]},"trialDetails":[{"nctId":"NCT07020065","phase":"PHASE2","title":"Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%","status":"NOT_YET_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2026-05","conditions":"Metastatic NSCLC - Non-Small Cell Lung Cancer","enrollment":156},{"nctId":"NCT07198074","phase":"PHASE3","title":"Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-01-27","conditions":"Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma","enrollment":255},{"nctId":"NCT06422143","phase":"PHASE3","title":"Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-10","conditions":"Non-small Cell Lung Cancer, NSCLC","enrollment":851},{"nctId":"NCT03914612","phase":"PHASE3","title":"Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-22","conditions":"Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma","enrollment":813},{"nctId":"NCT05256225","phase":"PHASE3","title":"Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-16","conditions":"Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma","enrollment":360},{"nctId":"NCT07061977","phase":"PHASE3","title":"Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-11-05","conditions":"Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma","enrollment":336},{"nctId":"NCT06096844","phase":"PHASE3","title":"Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-19","conditions":"Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8","enrollment":304},{"nctId":"NCT05806060","phase":"PHASE3","title":"Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-04-25","conditions":"Triple-Negative Breast Cancer","enrollment":134},{"nctId":"NCT07221474","phase":"PHASE2","title":"A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-12","conditions":"Squamous Non-small Cell Lung Cancer","enrollment":180},{"nctId":"NCT04095364","phase":"PHASE3","title":"Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2019-09-20","conditions":"Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma","enrollment":450},{"nctId":"NCT02654119","phase":"PHASE2","title":"Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2015-12-11","conditions":"HER2 Positive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7","enrollment":20},{"nctId":"NCT06915025","phase":"PHASE3","title":"Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer","status":"RECRUITING","sponsor":"Imunon","startDate":"2025-07-09","conditions":"Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer","enrollment":500},{"nctId":"NCT06493019","phase":"PHASE2","title":"Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer","status":"RECRUITING","sponsor":"Dustin Deming","startDate":"2024-09-30","conditions":"Anal Cancer","enrollment":23},{"nctId":"NCT05980169","phase":"NA","title":"The Effect of Low Frequency Soundwave Stimulation on Chemotherapy Induced Peripheral Neuropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Augusta University","startDate":"2023-11-29","conditions":"Gynecologic Cancer, Neuropathy;Peripheral","enrollment":80},{"nctId":"NCT07216703","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-19","conditions":"Cervical Cancer","enrollment":1023},{"nctId":"NCT06952504","phase":"PHASE3","title":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-22","conditions":"Endometrial Cancer","enrollment":1123},{"nctId":"NCT06726265","phase":"PHASE3","title":"Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immutep S.A.S.","startDate":"2025-03-21","conditions":"Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)","enrollment":756},{"nctId":"NCT07283705","phase":"PHASE2","title":"A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer","status":"SUSPENDED","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-05-18","conditions":"Phase 2 Study, BMS-986504, MTAP-deleted Pancreatic Cancer","enrollment":60},{"nctId":"NCT07472153","phase":"PHASE2, PHASE3","title":"PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer","status":"RECRUITING","sponsor":"N.N. Alexandrov National Cancer Centre","startDate":"2025-07-01","conditions":"Metastatic Cervical Cancer, Persistent Cervical Cancer, Recurrent Cervical Cancer","enrollment":120},{"nctId":"NCT04165070","phase":"PHASE1, PHASE2","title":"KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-12-19","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":450},{"nctId":"NCT07472140","phase":"PHASE2, PHASE3","title":"PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer","status":"RECRUITING","sponsor":"N.N. Alexandrov National Cancer Centre","startDate":"2025-07-01","conditions":"Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer","enrollment":120},{"nctId":"NCT06731413","phase":"PHASE2","title":"Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2025-02-11","conditions":"Non-Small Cell Lung Cancer, NSCLC, Advanced Non-Small Cell Lung Cancer","enrollment":40},{"nctId":"NCT07469241","phase":"PHASE2","title":"Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma.","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-03-10","conditions":"Advanced Esophageal Squamous Cell Carcinoma, Unresectable Esophageal Squamous Cell Carcinoma","enrollment":50},{"nctId":"NCT03164616","phase":"PHASE3","title":"Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-06-01","conditions":"Non Small Cell Lung Cancer NSCLC","enrollment":1186},{"nctId":"NCT06989112","phase":"PHASE3","title":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-27","conditions":"Endometrial Cancer","enrollment":600},{"nctId":"NCT05952453","phase":"PHASE2","title":"Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-02-17","conditions":"Ovarian Cancer","enrollment":20},{"nctId":"NCT05819892","phase":"PHASE1","title":"Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-07-17","conditions":"Endometrial Cancer","enrollment":21},{"nctId":"NCT05378334","phase":"NA","title":"Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients","status":"RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2022-06-15","conditions":"Non-small Cell Lung Cancer","enrollment":82},{"nctId":"NCT05689671","phase":"PHASE4","title":"Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nikolaj Frost MD","startDate":"2023-12-06","conditions":"Non-Small Cell Lung Cancer Metastatic","enrollment":136},{"nctId":"NCT07191418","phase":"NA","title":"Study-group on Palliative ERCP And RFA-ablation in Metastatic and Inoperable Pancreatic Tumors","status":"NOT_YET_RECRUITING","sponsor":"Roberto Valente","startDate":"2026-03","conditions":"Pancreatic Cancer Metastatic to Liver","enrollment":178},{"nctId":"NCT06194448","phase":"PHASE2","title":"To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-04-21","conditions":"Lung Cancer","enrollment":76},{"nctId":"NCT07454018","phase":"PHASE2","title":"Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-03-01","conditions":"Recurrent Ovarian Cancer, Platinum-sensitive Ovarian Cancer","enrollment":45},{"nctId":"NCT04222972","phase":"PHASE3","title":"A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2020-07-24","conditions":"RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm, Carcinoma, Non-Small-Cell Lung","enrollment":223},{"nctId":"NCT07065630","phase":"PHASE2","title":"Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-10-07","conditions":"Head and Neck Cancer, HPV","enrollment":38},{"nctId":"NCT07446335","phase":"PHASE3","title":"A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2026-04","conditions":"Advanced Esophageal Squamous Cell Carcinoma","enrollment":578},{"nctId":"NCT07033819","phase":"PHASE2","title":"Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-06-25","conditions":"Ovarian Cancer","enrollment":48},{"nctId":"NCT07435454","phase":"PHASE2","title":"Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2025-12-01","conditions":"Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma","enrollment":22},{"nctId":"NCT05739981","phase":"PHASE1, PHASE2","title":"Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer","status":"RECRUITING","sponsor":"Imunon","startDate":"2023-02-10","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":30},{"nctId":"NCT04605913","phase":"PHASE1, PHASE2","title":"Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-04-01","conditions":"Pancreas Cancer, Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma","enrollment":40},{"nctId":"NCT06802757","phase":"PHASE2","title":"Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-05-01","conditions":"Breast Cancer","enrollment":72},{"nctId":"NCT03976362","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-28","conditions":"Carcinoma, Squamous Cell, Non-small-cell Lung","enrollment":851},{"nctId":"NCT03088540","phase":"PHASE3","title":"Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2017-05-29","conditions":"Carcinoma，Non-Small-Cell Lung, Lung Carcinomas, Non-Small-Cell, Non-small-cell Lung Carcinoma","enrollment":712},{"nctId":"NCT04469556","phase":"PHASE2","title":"Pancreatic Adenocarcinoma Signature Stratification for Treatment","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2020-10-14","conditions":"Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Advanced Pancreatic Cancer","enrollment":150},{"nctId":"NCT07418866","phase":"PHASE2","title":"FANLUNG-2：The Value of High-Low Mixed-Dose Radiotherapy Combined With Chemo-Immunotherapy Induction in Locally Advanced Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-02","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer)","enrollment":70},{"nctId":"NCT05460000","phase":"PHASE2","title":"A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy","status":"RECRUITING","sponsor":"North Eastern German Society of Gynaecological Oncology","startDate":"2024-10-11","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma","enrollment":640},{"nctId":"NCT06783647","phase":"PHASE2","title":"A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2025-06-11","conditions":"Advanced Solid Tumour","enrollment":230},{"nctId":"NCT07392346","phase":"PHASE2","title":"Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Dai, Guanghai","startDate":"2025-12-01","conditions":"Gastric Cancer Adenocarcinoma Metastatic","enrollment":68},{"nctId":"NCT05775289","phase":"PHASE2","title":"A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-03-15","conditions":"Non-small Cell Lung Cancer","enrollment":182},{"nctId":"NCT06656598","phase":"PHASE2","title":"Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer","status":"RECRUITING","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2025-11-07","conditions":"Stage III NSCLC","enrollment":152},{"nctId":"NCT07400536","phase":"PHASE3","title":"A Clinical Study on the Treatment of LACC With Cadonilimab Combined With Chemotherapy Followed by CCRT","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-03-30","conditions":"Locally Advanced Cervical Carcinoma","enrollment":378},{"nctId":"NCT03775486","phase":"PHASE2","title":"Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-12-21","conditions":"Non-small Cell Lung Cancer NSCLC","enrollment":401},{"nctId":"NCT06964568","phase":"PHASE3","title":"CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-02-01","conditions":"Esophageal Carcinoma, Radiotherapy, Immunotherapy","enrollment":452},{"nctId":"NCT03579394","phase":"NA","title":"Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer","status":"COMPLETED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2018-10-19","conditions":"Ovarian Cancer Stage IV, Ovarian Cancer Stage IIIC, Ovarian Cancer Stage IIIb","enrollment":211},{"nctId":"NCT05415215","phase":"PHASE3","title":"A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-07-05","conditions":"Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer","enrollment":346},{"nctId":"NCT06052839","phase":"PHASE2","title":"Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC","status":"RECRUITING","sponsor":"Dan Zandberg","startDate":"2023-10-03","conditions":"Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)","enrollment":15},{"nctId":"NCT07384416","phase":"PHASE2","title":"Single-Arm Trial of QL1706, Lenvatinib, and Nab-Paclitaxel for Advanced Refractory Penile Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-10","conditions":"Penile Cancer","enrollment":47},{"nctId":"NCT02525757","phase":"PHASE2","title":"MPDL3280A With Chemoradiation for Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-01-26","conditions":"Lung Cancer, Non-Small Cell Lung Cancer","enrollment":52},{"nctId":"NCT05621707","phase":"PHASE2","title":"Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2022-11-02","conditions":"Esophageal Squamous Cell Carcinomas, Concurrent Chemoradiotherapy, Immunotherapy","enrollment":50},{"nctId":"NCT05502237","phase":"PHASE3","title":"Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-10-12","conditions":"Non-small Cell Lung Cancer","enrollment":1021},{"nctId":"NCT07361991","phase":"PHASE1, PHASE2","title":"IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2026-03","conditions":"Advan'ce'd, Advanced","enrollment":50},{"nctId":"NCT03377491","phase":"PHASE3","title":"Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)","status":"COMPLETED","sponsor":"NovoCure Ltd.","startDate":"2018-05-10","conditions":"Pancreas Adenocarcinoma","enrollment":571},{"nctId":"NCT05909332","phase":"PHASE3","title":"Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-06-20","conditions":"Breast Cancer, Triple Negative Breast Cancer","enrollment":764},{"nctId":"NCT06746116","phase":"PHASE3","title":"A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-12-30","conditions":"Advanced or Recurrent Endometrial Cancer","enrollment":45},{"nctId":"NCT05296798","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-07-18","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":922},{"nctId":"NCT06654011","phase":"PHASE2","title":"IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 Trial","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-02-17","conditions":"Cervical Adenocarcinoma, Gastric-type Endocervical Adenocarcinoma","enrollment":25},{"nctId":"NCT07328802","phase":"PHASE2","title":"Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-01-01","conditions":"ORR,OS,PFS","enrollment":25},{"nctId":"NCT07328854","phase":"PHASE3","title":"40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Ming-Yuan Chen","startDate":"2025-11-20","conditions":"Nasopharyngeal Carcinoma","enrollment":346},{"nctId":"NCT05481645","phase":"PHASE2","title":"Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-08-26","conditions":"Advanced Endometrial Cancer, Sarcoma of Uterus","enrollment":71},{"nctId":"NCT05613413","phase":"PHASE2","title":"A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2022-12-28","conditions":"Metastatic Squamous Non-Small Cell Lung Carcinoma","enrollment":36},{"nctId":"NCT04332367","phase":"PHASE2","title":"Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2020-08-01","conditions":"Non-small Cell Lung Cancer","enrollment":59},{"nctId":"NCT07318883","phase":"PHASE2, PHASE3","title":"A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-03","conditions":"Squamous NSCLC","enrollment":720},{"nctId":"NCT04872985","phase":"PHASE2","title":"Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-04-20","conditions":"Breast Cancer, Hormone-receptor Positive Breast Cancer","enrollment":140},{"nctId":"NCT04578106","phase":"PHASE2","title":"Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy","status":"TERMINATED","sponsor":"Fundacio Clinic Barcelona","startDate":"2020-09-23","conditions":"HER2-positive Breast Cancer, Stage I Breast Cancer","enrollment":5},{"nctId":"NCT03602859","phase":"PHASE3","title":"A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tesaro, Inc.","startDate":"2018-10-11","conditions":"Ovarian Neoplasms, Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma","enrollment":1400},{"nctId":"NCT07310771","phase":"PHASE2","title":"Sintilimab-Nimotuzumab Induction Followed by Chemoradiation-Nimotuzumab in LA-HNSCC: Single-Arm Phase II","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2026-01-10","conditions":"Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-SCCHN)","enrollment":23},{"nctId":"NCT02270814","phase":"PHASE2","title":"Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2015-02-02","conditions":"Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Head and Neck","enrollment":74},{"nctId":"NCT07307443","phase":"PHASE2","title":"A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Zhijie Wang","startDate":"2026-02-01","conditions":"SMARCA4-Deficient Tumor, Locally Advanced or Metastatic Lung Cancer","enrollment":28},{"nctId":"NCT06725368","phase":"PHASE2","title":"Carboplatin + Paclitaxel + Cetuximab (PCC) After Failure of Pembrolizumab +/- First-line Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck","status":"RECRUITING","sponsor":"Centre Paul Strauss","startDate":"2025-01-24","conditions":"Head and Neck Cancer","enrollment":46},{"nctId":"NCT04269200","phase":"PHASE3","title":"Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-05-05","conditions":"Endometrial Neoplasms","enrollment":805},{"nctId":"NCT02726997","phase":"PHASE1, PHASE2","title":"Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-07-06","conditions":"Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7","enrollment":18},{"nctId":"NCT07290010","phase":"PHASE2","title":"The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-09-26","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":25},{"nctId":"NCT03245892","phase":"PHASE1","title":"A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-08-04","conditions":"High Grade Serous Ovarian, Fallopian Tube, Primary Peritoneal Cancer","enrollment":27},{"nctId":"NCT07285434","phase":"EARLY_PHASE1","title":"Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Biogenea Pharmaceuticals Ltd.","startDate":"2026-02-02","conditions":"NSCLC (Non-small Cell Lung Cancer), Squamous Lung Cancer With FGFR1 Amplification, Non-Squamous Non Small Cell Lung Cancer","enrollment":90},{"nctId":"NCT05024773","phase":"PHASE3","title":"Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)","status":"RECRUITING","sponsor":"Fidia Farmaceutici s.p.a.","startDate":"2022-12-29","conditions":"Bladder Carcinoma in Situ (CIS)","enrollment":112},{"nctId":"NCT07283991","phase":"PHASE2","title":"QL1706 Plus Chemotherapy for Borderline Resectable Esophageal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-12-30","conditions":"Esophageal Cancer","enrollment":24},{"nctId":"NCT06795009","phase":"PHASE1","title":"Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-10-17","conditions":"Uterine Cancer, Endometrial Cancer","enrollment":36},{"nctId":"NCT07271602","phase":"PHASE2","title":"A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-01-30","conditions":"Non Small Cell Lung Cancer, Immunotherapy, Radiotherapy","enrollment":104},{"nctId":"NCT07176702","phase":"PHASE2","title":"A Phase II Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-09-30","conditions":"Metastatic PDAC, HER2-positive Status","enrollment":45},{"nctId":"NCT04753879","phase":"PHASE2","title":"Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2021-09-29","conditions":"Metastatic Pancreatic Cancer","enrollment":38},{"nctId":"NCT03249142","phase":"PHASE1, PHASE2","title":"Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer","status":"COMPLETED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2017-10-18","conditions":"Ovarian Cancer","enrollment":69},{"nctId":"NCT07258147","phase":"PHASE2","title":"Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases","status":"NOT_YET_RECRUITING","sponsor":"Sichuan University","startDate":"2025-12-25","conditions":"Lung Cancer (SCLC)","enrollment":30},{"nctId":"NCT05664971","phase":"PHASE1, PHASE2","title":"JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2023-02-09","conditions":"Advanced Lung Cancer","enrollment":119},{"nctId":"NCT06843681","phase":"PHASE2","title":"Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study","status":"ENROLLING_BY_INVITATION","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-03-01","conditions":"Breast Carcinoma in Situ","enrollment":54},{"nctId":"NCT06846346","phase":"PHASE2","title":"Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-11-20","conditions":"Metastatic Esophageal Adenocarcinoma, Advanced Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma","enrollment":88},{"nctId":"NCT05631899","phase":"PHASE1","title":"CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2023-04-03","conditions":"Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V","enrollment":9},{"nctId":"NCT07153445","phase":"PHASE2","title":"Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Fundación GECP","startDate":"2025-07-08","conditions":"Non Small Cell Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer","enrollment":97},{"nctId":"NCT05690945","phase":"PHASE3","title":"A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2023-02-15","conditions":"Lung Cancer","enrollment":606},{"nctId":"NCT07233850","phase":"PHASE2","title":"A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers","status":"NOT_YET_RECRUITING","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","startDate":"2025-11","conditions":"Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)","enrollment":300},{"nctId":"NCT07233252","phase":"PHASE2","title":"Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Second Hospital","startDate":"2025-11-25","conditions":"Renal Pelvic Carcinoma, Tislelizumab, PD-1 Inhibitor","enrollment":35},{"nctId":"NCT03740165","phase":"PHASE3","title":"Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-18","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms","enrollment":1367}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1156,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Abraxane (Maintenance)","genericName":"Abraxane (Maintenance)","companyName":"Celgene","companyId":"celgene","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Abraxane is a nanoparticle albumin-bound paclitaxel that stabilizes microtubules to inhibit cell division and induce apoptosis in cancer cells. Used for Metastatic non-small cell lung cancer (maintenance therapy), Metastatic breast cancer, Pancreatic cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}